InvestorsHub Logo
Followers 827
Posts 119477
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 766

Monday, 11/15/2021 11:40:34 AM

Monday, November 15, 2021 11:40:34 AM

Post# of 1162
BMY presents phase-2 Milvexian data at AHA:

https://www.businesswire.com/news/home/20211115005987/en

Milvexian is an oral anticoagulant that inhibits Factor XIa, a new MoA. Compared to FXa inhibitors such as Eliquis and Xarelto, Milvexian may be able to offer comparable efficacy with less bleeding risk.

BMY is developing Milvexian with JNJ, pursuant to a 2018 collaboration (#msg-140083631). BMY hopes Milvexian can replace some or all of the revenue from Eliquis, which loses exclusivity in 2028. Phase-3 trials for Milvexian are slated to start in 2022.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News